Universal Registration Document Including the Annual Financial Report

The report describes OSE Immunotherapeutics' ongoing pivotal Phase 3 ARTEMIA trial for Tedopi and reports consolidated 2025 revenues of 2,619 thousand euros, down from 69,877 thousand euros in 2024. Its CSR Charter covers governance, human rights, employee relations, environmental practices, and business ethics. The company also describes plans to evaluate its existing CSR actions against ISO 26000.